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Equine Protozoal Myeloencephalitis 
Avery Warschauer Brickson, DVMt and Axel Sondhof, DVMtt 
Disease 
Equine protozoal myeloencephalitis (EPM) 
is a neurologic disease of horses caused by 
the apicomplexan protozoa Sarcocystis 
neurona, an organism which is thought to 
be genetically identical to Sarcocystis 
falcatula. 1 Sarcocystis neurona has a two-
host life cycle which is perpetuated when a 
carnivore or an omnivore consumes the flesh 
of an infected intermediate host containing 
sarcocysts (the encysted stages of the para-
site).2 The opossum is the primary host of 
the parasite, while birds are intermediate 
hosts; the horse is merely an aberrant, dead-
end host. 1 
Mature parasites live in the intestinal 
tract of the opossum and the sporocysts are 
passed in its feces. 1,2 These sporocysts can 
survive in the environment for up to a year 
or more.2 Birds then consume the parasite 
via fecally contaminated food or water.3 The 
parasite penetrates the intestine and divides 
asexually in the vascular endothelium.3 The 
resulting merozoites eventually travel 
through the blood stream to the skeletal 
muscle. Once there, they develop into 
sarcocysts, ready to be consumed by preda-
tor or scavenger and to complete their life 
cycle in the intestine.3 
When a horse consumes water or feed 
which is contaminated with sporocysts, the 
sporozoites penetrate the intestine and en-
ter the blood stream to replicate in the en-
dothelial cells of the blood vessels. How-
ever, instead oflocalizing in skeletal muscle, 
the parasites penetrate the damaged blood 
vessels of the blood-brain barrier, enter the 
neurons, and reproduce asexually in the 
CNS tissues.4 The inflammatory response 
that the horse mounts against the replicat-
ing parasite along with the parasite itself 
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causes progressive damage to the neural tis-
sues, leading to the clinical signs associated 
with neurologic disease. The incubation 
period of the disease is extremely variable 
and stress may increase the likelihood of 
developing clinical disease.2,5 
Incidence and Prevalence 
Sarcocystis neurona is not contagious from 
horse to horse since schizonts (the product 
of asexual reproduction) are not infective 
and sarcocysts do not develop in equine cen-
tral nervous system tissue,4 EPM occurs in 
horses throughout the western hemisphere 
(since there are no opossums in the eastern 
hemisphere).2 EPM demonstrates no sex or 
age predilection as compared to other neu-
rological diseases,5 Current studies suggest 
a trend of decreasing risk from younger to 
older horses,5 In addition, Warmbloods, 
Thoroughbreds, and Standardbreds may be 
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at a higher risk of dis-
ease.5 At least one recent 
study suggests that 
horses who are fre-
quently re-exposed to the 
parasite may actually 
develop some degree of 
protective immunity; 
more extensive research 
in this area may lead to 
the development of an 
EPM vaccine.6 
Clinical Signs 
The clinical signs of 
EPM vary tremendously 
from case to case. Neu-
rologic signs may show 
An aggregate of merozoites typical of Sarcocystis falculata is present 
in the center. In addition, changes in the spinal cord include axonal 
degeneration and gliosis. 
characteristics of brain, brainstem and/or 
spinal cord disease and may appear focal or 
multifocal. 4 Onset of the disease may be 
acute or insidious and may take as few as 
28 days to as long as two years.6 Clinical 
signs may include, but are not limited to, 
abnormal upper airway function, unusual 
lameness or gait abnormality with abnor-
mal hoof wear, weakness, focal or asymmet-
ric muscle atrophy, ataxia, spasticity, de-
creased proprioception, areas of hypalgesia 
or complete sensory loss and depression.3•4 
Cranial nerve signs such as a head tilt, fa-
cial nerve paralysis, and difficulty swallow-
ing may also be observed.4 Neurologic symp-
toms ofEPM are almost always asymmetric. 
This asymmetry makes distinguishing EPM 
from other neurologic diseases of the horse 
easier. Other CNS disease such as cervical 
vertebral malformation, myelopathy, and 
Equine herpes virus myelitis often present 
with symmetric neurologic signs. 4 In addi-
tion, most horses that are infected with EPM 
have normal bloodwork.4 
The disease is progressive and can be 
fatal ifleft untreated. The course of the dis-
ease is highly variable, and in some cases, 
the condition of the horse may appear to sta-
bilize and remain static for a period oftime.4 
An infected horse may develop pain and 
lameness secondary to asymmetric neuro-
logic signs as it attempts to compensate for 
the instability. A horse may have a luxat-
ing patella on the affected side due to muscle 
weakness that was not previously present. 
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Very early in the course of the disease, a 
conscientious rider or handler may detect 
slight changes in performance such as as 
"clumsiness" or imbalances never felt or 
seen before. As the disease progresses, an 
infected horse may sustain various injuries 
resulting from difficulties rising to a stand-
ing position after lying down. 
Diagnosis and Necropsy Findings 
Many factors should be considered when 
diagnosing EPM including sensitivity and 
specificity of every test. Test sensitivity is 
defined as the proportion of diseased ani-
mals that actually test positive.7 On the 
other hand, text specificity is defined as the 
proportion of non-diseased animals that ac-
tually test negative7• Sensitivity and speci-
ficity are fixed characteristics of each indi-
vidual test and do not change according to 
the disease prevalence within a population. 
Test information can not be effectively ap-
plied without understanding the positive 
and negative predictive values which change 
for each test depending upon the disease 
prevalence within the tested population. 
The positive predictive value is defined as 
the proportion of animals testing positive 
that are truly diseased.7 The negative pre-
dictive value is defined as the proportion of 
animals testing negative that are not dis-
eased.7 In addition, one must consider the 
stage or severity of disease in each particu-
lar horse involved. Finally, one must also 
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look at the prevalence of disease in each 
geographic area. 
Two tests are typically used when diag-
nosing EPM. Western immunoblotting is 
used to test for antibodies to EPM in either 
serum or cerebral spinal fluid (CSF). It is 
well known that testing for serum antibod-
ies against Sarcocystis neurona is oflimited 
value when diagnosing EPM because posi-
tive serum indicates an immune response 
due to exposure only. 2 Instead, diagnosis 
should be made from a clean sample ofCSF. 
A clean sample means that the CSF has not 
been contaminated with blood or blood com-
ponents. This contamination can occur as a 
result ofa compromised blood-brain barrier 
with leakage of blood proteins (including 
antibodies into the CSF) or as a result of 
blood contamination during tap procedure. 
The potential for contamination and false 
positive results of Western immunoblotting 
analysis has prompted the development of 
CSF indices that can be used to determine 
if blood contamination of the CSF sample 
has occurred. The indices compare blood 
levels ofIgG and albumin with the CSF lev-
els ofIgG and albumin.8 The albumin quo-
tient (AQ) is equal to 100 times the concen-
tration of albumin in the CSF divided by the 
concentration of albumin in the serum.4 A 
value of 2.0 or greater suggests leakage of 
the blood-brain barrier has occurred. The 
IgG index is equal to the serum albumin 
concentration divided by the CSF albumin 
concentration and multiplying that quantity 
by the quotient of the IgG concentration in 
the CSF divided by the serum IgG concen-
tration.4 A value greater than 0.3 is consid-
ered abnormally elevated.4 Increased AQ 
coupled with increased IgG index indicates 
increased blood-brain permeability or in-
creased production of intrathecal antibody.4 
Increased AQ with a normal IgG index indi-
cates increased blood-brain barrier perme-
ability, while a normalAQ with an increased 
IgG index indicates increased intrathecal 
antibody production.4 These indices are es-
sential to determine the validity of test re-
sults when using Western blot analysis of 
CSF. 
The second EPM diagnostic test is the 
polymerase chain reaction (PCR). PCR de-
tects ribosomal RNA of the organism 
present in the CSF.4 It is often used to 
back up results of Western immuno-
bloting analysis. When using Western 
Blot analysis to test for antibody to Sar-
cocystis neurona in CSF from a popula-
tion in an area oflow prevalence, the posi-
tive predictive value is very low7 since 
very few clinically normal horses have 
EPM compared to horses that show neu-
rologic signs; therefore, Western blot 
analysis of CSF fluid obtained from clini-
cally normal horses is not a reliable 
method of determining whether or not a 
horse has EPM.7 PCR can confirm that a 
horse may be in the very early signs of the 
disease. 
Necropsy findings can range from mi-
croscopic to grossly visible le-
sions.4 The lesions, character-
ized by mild to severe necrosis 
and suppurative myelo-encepha-
litis with mononuclear and giant 
cell infiltration,4 are often mul-
tifocal but always confined to the 
CNS.4 
Treatment 
White matter of spinal cord. Note the axonal degeneration, 
necrosis, and gliosis. In addition, there are everal perivascu-
lar cuffs of lymphocyte ,pia ma cells and gitter cells. 
Standard treatment for EPM in-
cludes at least twelve weeks of a 
combination of potentiated sul-
fonamides at 15 - 20 mglkg orally 
BID and pyrimethamine at 1mgl 
kg SID.9 If a horse with EPM does 
not respond in 30 days, a system-
atic increase of medication dos-
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ages is suggested every 30 days, keeping in 
mind the mechanism of action of the afore 
mentioned drugs.9 More research is needed 
to understand how to safely implement in-
creased dosages into a treatment program. 
The use of these drugs is intended to 
produce a sequential blockade of folic acid 
metabolism in the parasite; therefore, folic 
acid deficiency anemia (+I-thrombocytope-
nia or neutropenia) can be an adverse effect 
of the treatment.4 To prevent this possible 
complication, folic acid supplementation 
(along with vitamin E) has been recom-
mended in addition to regular complete 
blood counts at two-week intervals.4 The 
organism cannot use preformed folic acid 
while the horse can.4 
Recent studies have shown pregnant 
mares that have been treated for EPM with 
sulfonamides, pyrimethamine, folic acid, 
and vitamin E have been known to produce 
foals with congenital defects such as bone 
marrow aplasia and hypoplasia, renal neph-
rosis or hypoplasia, and skin lesions.10 For 
this reason, dietary folic acid supplements 
are not currently recommended for pregnant 
mares. In addition, these drugs may cause 
reduced spermatogenesis in stallions.9 
Two recently introduced drugs, 
Diclazuril® and Toltrazuril®, are being con-
sidered in the treatment of EPM. Both are 
triazine-based agents ll that appear to have 
a very low toxicity in mammals, are well-
absorbed orally, have long plasma half-lives, 
and are toxic against Sarcocystis neurona. 12 
These drugs are currently being extensively 
tested, researched, and show a great deal of 
potential in the future treatment of EPM. 
Finally, anti-inflammatory agents may 
be used (especially in acute cases) such as 
dimethyl sulphoxide, flunixin meglumine, 
and phenylbutazone.4 Corticosteroids are 
not recommended; however, short-term use 
(1-3 days) may be necessary in a severely 
debilitated animaJ.2 
Treatment appears to result in recovery 
of approximately 60% of the cases and 
greater than 60% of the cases appear to re-
spond to therapy.9 The duration of treat-
ment beyond 60 to 90 days is dependent 
upon the regression of clinical signs and the 
point at which the CSF no longer remains 
positive. Although some horses remain CSF 
positive with the Western blot for a year or 
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more, continuation of the treatment for 30 
days after clinical improvement has ceased 
is generally recommended.2 It is important 
to avoid periodic or intermittent treatment, 
as this may lead to parasite resistance.9 
Failure to respond to continuous treatment 
generally necessitates euthanasia.4 
Conclusion 
Our knowledge ofEPM grows daily, and the 
speed at which we are learning about this 
disease is remarkable. However, EPM pre-
sents the equine practitioner with a monu-
mental challenge: Keeping up with the con-
stant flow of new information and sorting 
out what is valid will allow faster, more ef-
fective diagnosis and treatment and will 
decrease the loss of horses' lives and careers 
to this disease .• 
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